These findings posit that FASN positively regulates sphingolipid metabolism through the expression of sphingosine kinases, in particular Sphk2, and that targeting FASN/SphK/S1P signaling could provide novel therapeutic strategy for treating metastatic colorectal cancer [78]. The gene discussed is FASN; the disease is metastatic colorectal cancer.